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Abstract Patients with systemic lupus erythematosus (SLE)
have an increased expression of type I interferon (IFN)-regu-
lated genes (an IFN signature), which is caused by an ongoing
production of type I IFNs by plasmacytoid dendritic cells
(pDCs). The reasons behind the continuous IFN production
in SLE are the presence of self-derived IFN inducers and a
lack of negative feed-back signals that downregulate the IFN
response. In addition, several cells in the immune system pro-
mote the IFN production by pDCs and gene variants in the
type I IFN signaling pathway contribute to the IFN signature.
The type I IFNs act as an immune adjuvant and stimulate T
cells, B cells, and monocytes, which all play an important role
in the loss of tolerance and persistent autoimmune reaction in
SLE. Consequently, new treatments aiming to inhibit the ac-
tivated type I IFN system in SLE are now being developed and
investigated in clinical trials.
Keywords Type I interferon . Systemic lupus erythematosus .
Plasmacytoid dendritic cells . Etiopathogenesis . Immune
regulation
Introduction
Systemic lupus erythematosus (SLE) is the prototype autoim-
mune disease, characterized by a very large number of differ-
ent autoantibodies, immune complex formation, and organ
inflammation. In addition, the majority of patients with SLE
display an increased expression of type I interferon (IFN)-
regulated genes, also known as an IFN signature. This obser-
vation together with previous reports that IFN-α therapy can
induce an SLE syndrome suggested that the IFN signature
reflects an important role of the type I IFN system in the
etiopathogenesis of the disease [1, 2]. Studies during the last
decade have revealed a number of environmental and genetic
factors that can contribute to the ongoing activation of the type
I IFN system in SLE. Furthermore, the regulation and control
of the type I IFN production in SLE are disturbed with a lack
of proper negative feedbackmechanisms. Consequently, it has
been suggested that the type I IFN system is one of the driving
forces behind the disease and a number of treatment strategies
aiming to downregulate IFN production in SLE have been
developed. In the present review, we will mainly focus on
cellular interactions involved in the activation and regulation
of the type I IFN production by plasmacytoid dendritic cells
(pDCs), the main type I IFN producing cell, and how an on-
going activation of the type I IFN system can contribute to the
SLE disease process.
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is one of the most het-
erogeneous autoimmune diseases with multisystemic presen-
tation and a wide range of clinical and serological manifesta-
tions [3, 4]. The disease varies between individual patients
from relatively mild manifestations of skin and joints to life-
threatening renal and central nervous system involvement [4].
Besides clinical heterogeneity, SLE patients also demonstrate
immunological heterogeneity, indicating multiple pathogenic
mechanisms. Consequently, patients with SLE can re-
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More than 200 different autoantibodies have been de-
scribed in SLE, which partly may explain the diverse clinical
phenotypes [6]. However, the most commonly found autoan-
tibodies are directed against single-stranded (ss) and double-
stranded (ds) DNA, Ro/La antigens, and ribonuclear protein
(RNP), which can be present years before the clinical onset of
SLE [7]. Some of the autoantibody specificities have been
associated with distinct clinical manifestations or disease ac-
tivity, e.g., anti-dsDNA and anti-Ro antibodies correlate with
renal disease and photosensitive skin rash, respectively [8].
Patients with SLE have an ongoing IFN-α production,
which gives rise to the IFN signature that can be demonstrated
in approximately 50 % of adult SLE patients and the majority
of children with SLE [9]. Several studies have found an asso-
ciation between the IFN signature and multiple clinical man-
ifestations, such as nephritis and CNS engagement [10, 11],
and recent data suggest that patients with a high type I IFN
signature represent a distinct subset of SLE patients that re-
spond to type I IFN blockade, see below.
Activation of type I interferon production
The type I IFN family comprises 13 IFN-alpha (-α) subtypes
and one copy of IFN-β, IFN-ε, IFN-κ and IFN-ω, respective-
ly. Normally, the IFN-α and IFN-β production is strictly con-
trolled but starts rapidly when viral or bacterial nucleic acids
are sensed by pattern recognition receptors (PRRs), such as
certain Toll-like receptors (TLRs) or cytoplasmic nucleic acid
sensors [12]. The route activated depends on the PRR reper-
toire of the responding cell type and the subcellular localiza-
tion of the immunostimulatory nucleic acid.
The TLRs involved in the type I IFN production are mainly
present in immune cells where they are located in the
endolysosomal compartment sensing double-stranded (ds)
RNA (TLR3), single-stranded (ss) RNA (TLR7/8), and
dsDNA containing unmethylated CpG motifs (TLR9) [13].
The latter is also reported to sense RNA/DNA hybrids which
are generated during replication of several types of viruses
[14].
Two cell types that are capable of secreting large amounts
of IFN-α and IFN-β are plasmacytoid dendritic cells (pDCs)
and monocytes. The latter respond mainly to dsRNA and cer-
tain RNAviruses such as Sendai and influenza virus, whereas
pDCs can be triggered to secrete type I IFN by almost all
viruses and some bacteria [15]. pDCs express TLR3, TLR7,
and TLR9 and have a high basal level of interferon regulatory
factor (IRF) 7, which contribute to the rapid and massive onset
of IFN-α production (1–3 pg per cell) [16]. Another group of
molecules important for initiating the type I IFN production
consists of cytoplasmic RNA sensors such as RNA helicases
that are expressed by many different cell types. In addition,
several cytosolic DNA sensors have recently been described
including DNA-dependent activator of IFN-regulatory factor
1 (DAI) and cGMP-AMP synthase (cGAS), with suggested
roles in recognizing pathogen-derived dsDNA as well as in-
completely digested self-DNA [17, 18]. Taken together, there
seems to be a redundancy of nucleic acid sensing immune
receptors, and it remains to be clarified how these are involved
in the recognition of DNA and RNA of endogenous origin and
what the consequences are if they are not regulated properly.
Type I interferon production in SLE
Several possible mechanisms behind the ongoing type I IFN
production in SLE have been implicated during the last years.
One important mechanism of IFN-α induction in SLE is me-
diated by interferogenic ICs, which are immune complexes
consisting of autoantibodies and nucleic acid-binding proteins
that are endocytosed through FcγRIIa on pDCs and
transported into the endosomes where the nucleic acid part
of the IC interacts with TLR7 or TLR9 [19, 20]. Type I IFN
production by pDCs can also be trigged by neutrophil extra-
cellular traps (NETs) [21]. The NETosis is a relatively recently
described cell death pathway where neutrophils extrude nu-
clear material such as decondensated chromatin, histones,
granular, and cytoplasmic proteins in a web-like structure
which can entrap invading pathogens. It was shown that a
subset of SLE patients have an impaired capacity to degrade
NETs due to decreased function of extracellular DNAse I,
which increases the exposure of nucleic acids and proteins
available to autoantibodies and autoreactive B cells [22, 23].
This could also lead to further stimulation of pDCs to produce
IFN-α. Recently, Lood et al. demonstrated that mitochondria-
derived ROS initiated NETosis and release of oxidized
mtDNA which can induce IFN-α via activation of the cyto-
solic cGAS stimulator of interferon genes (STING) pathway
or via the endosomal TLR9 pathway [24]. In summary, mul-
tiple immune mechanisms have evolved to react to nucleic
acids in different cellular compartments, and one of the critical
risk factors for SLE could be the increased exposure of nuclear
contents to such nucleic acid sensors.
Signaling via the type I IFN receptor
All type I IFNs bind, albeit with slightly different affinity, to
the same heterodimeric type I IFN receptor (IFNAR1)
expressed on the cell surface of most cell types [25].
Binding of type I IFNs to IFNAR1 initiates signaling cascades
through multiple pathways. The most thoroughly character-
ized type I IFN signaling pathway is the Janus activating ki-
nase (JAK)-signal transducer and activator of transcription
(STAT) pathway involving phosphorylation of cytoplasmic
JAK1 and tyrosine kinase (TYK) 2, and subsequently STAT
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1 and 2. A complex of activated STAT1 and 2 together with
IRF9 translocates to the nucleus where it binds to IFN regu-
latory elements and triggers transcription of several hundreds
of type I IFN-stimulated genes (ISGs) [25, 26]. Other mem-
bers of the STAT family, e.g., STAT3, 4, and 5 can also be
activated by type I IFNs but instead bind to IFN-γ-activated
response (GAS) elements. In addition, other signaling path-
ways such as MAPK (p38 and ERK) and PI3K/AKT can be
activated by IFNAR engagement and either cooperate with the
JAK/STAT pathway or act independently to trigger expression
of ISGs [27].
Environmental factors triggering IFN production
in SLE
There are a number of environmental factors that can both
induce an SLE syndrome and trigger a flare of the disease.
Several of these factors are by various mechanisms potent
activators of the type I IFN system. Ultraviolet (UV)-B light
is perhaps the most well-known environmental trigger of SLE
flares and can induce severe systemic manifestations beyond
the cutaneous reactions in photosensitive patients [28, 29].
Multiple mechanisms are involved in the UV light-induced
exacerbation of SLE, but important are the induction of type
I and III IFNs as well as chemokines. Type III IFNs acts via a
separate receptor but induce similar effects as type I IFNs and
are important for the protection of epithelial cells against vi-
ruses [30]. Thus, UV light (290–320 nm) exposure causes
redistribution of nuclear antigens to be exposed on the cell
surface and also triggers apoptosis and secondary necrosis of
keratinocytes [29]. In this way, normally hidden autoantigens,
such as nucleoproteins, can be recognized by autoantibodies
and form interferogenic immune complexes that induce type I
IFN production by pDCs in the skin [29]. In addition, UV
light can induce release of reactive oxygen species which
cause DNA strand breaks and pyrimidine dimer formation in
DNA further facilitating the availability of the nucleic acids
for IC formation [28].
In SLE, the pDCs are localized in peripheral organs, such
as skin and kidneys, where they are exposed to interferogenic
ICs, chemokines, and other stimulatory cytokines [16]. For
example, it has been shown that keratinocytes from patients
with cutaneous lupus and several other inflammatory skin
diseases produce high levels of type III IFNs [31]. The
keratinocyte-derived type III IFNs and the chemokine
CXCL9 recruit more inflammatory cells into the skin but
probably also Bprime^ the activated pDCs to enhanced type
I IFN production. Recently, it was discovered that UV irradi-
ation of keratinocytes enhanced the activation of the STING/
IRF3 signaling pathway in response to cytosolic DNA due to
loss of Unc51-like kinase 1 which is a negative regulator of
STING [32]. Such mechanism could lead to upregulated type
III IFN production and priming of pDC function in the pres-
ence of RNA recognized by TLR3. Taken together, sun expo-
sure can trigger and enhance the type I IFN production in the
skin of SLE patients leading to local as well as systemic ef-
fects and increased disease activity.
A large number of drugs have been reported to induce an
SLE-like syndrome (drug-induced lupus: DIL) with various
clinical and serological symptoms that dissolve when the
medication is withdrawn [33]. The most well-known drugs
inducing DIL are procainamide and hydralazine, reviewed in
[33]. Procainamide is an inhibitor of methyltransferase and
prevents DNA methylation, which can affect the regulation
of gene expression. Interestingly, recent studies have revealed
that methylation of nonhistone proteins is a highly dynamic
process which together with phosphorylation regulates signal
transduction as shown for example for STAT3 in the JAK/
STAT pathway [34]. In addition, antibodies to chromatin and
nucleosomes are commonly found in DIL as well as reduced
clearance of apoptotic cells [33].
It is common that infections trigger the onset of SLE or a
disease flare. Even though many viruses have been implicated
in the SLE etiology, no specific virus has been identified to
cause the disease. As microbial RNA and DNA can be recog-
nized by multiple nucleic acid sensors and thereby induce
production of type I IFNs, this may be the mechanism where-
by several microorganisms can contribute to the development
and relapse of SLE.
The genetic background to SLE
SLE has a strong familial aggregation and a higher disease
concordance rate between monozygotic twins (24–40 %)
compared to dizygotic twins or other siblings (2–5 %) [35,
36]. Genome-wide association studies (GWAS) have identi-
fied more than 50 SLE-associated genetic loci, most of which
affect pathways implicated earlier in SLE etiopathology, such
as immune complex processing, Toll-like receptor signaling,
and type I IFN production/response [37–39]. Notably, more
than half of the loci are connected to the type I IFN system
[40], including IRF5, TYK2, and STAT4, which are central for
activation of the type I IFN production and signaling [27].
However, the exact function of most of the risk gene variants
is unknown, but some gene variants were shown to correlate
with a certain phenotype, such as the risk IRF5 haplotype that
is associated with increased serum IFN activity in SLE pa-
tients [41]. Surprisingly, we found that the IRF5 risk haplo-
type was associated with a lower IFN-α production in pDCs
from healthy individuals stimulated with RNA-IC, compared
to the production by pDCs with the protective haplotype [42].
This could be interpreted as a result of the disease-specific
microenvironment in SLE patients compared to healthy indi-
viduals. The conclusion to be drawn from the study is that
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SLE risk variants can either contribute to increased or de-
creased type I IFN production, but the net effect is determined
by the combined effect of a large number of gene variants.
Although SLE is considered as a complex disorder, rare
SLE cases with a Mendelian mode of inheritance have been
described [40, 43]. Some of these monogenic SLE diseases
are now categorized as type I interferonopathies, due to the
prominent type I IFN signature.
The most well-known monogenic defects associated with a
high risk for SLE are loss-of-function mutations in C1q and
C4, encoding components of the classical complement path-
way, and in the 3′-5′ exonuclease TREX1 [44, 45], the latter
leading to accumulation of intracellular DNA that triggers
type I IFN production. The complement system is important
in the clearance of immune complexes, and it has been shown
that C1q inhibits the production of IFN-α and several other
cytokines by pDCs [46, 47], which could explain the in-
creased type I IFN production in C1q deficiencies. Although
SLE-associated risk alleles of C1q, C4, and TREX1 are rare in
the population, they confer a high relative risk for SLE.
Effects of type I IFN on the immune system
Type I IFNs have a broad spectrum of effects on innate and
adaptive immune responses [10, 48], but the actual mode of
action is dependent on the responding cell type as well as the
cellular and genetic context [49]. Also, the effects of IFN
subsets vary, probably due to a differential binding to the
IFNAR receptors subunits [50].
In addition to the direct antiviral effects, both IFN-α and
IFN-β efficiently enhance the effector capacity of natural kill-
er (NK) cells and macrophages against intracellular microbes
in the first-line immune defense [51]. In addition, expression
of MHC I molecules is increased by type I IFN on several cell
types, which facilities the cross-presentation of exogenous
antigens as well as detection of virus infected cells by cyto-
toxic T cells [52]. See Table 1.
IFN-α promotes the expression of MHC II and co-
stimulatory molecules, such as CD40, CD80, CD86, and pro-
duction of several cytokines stimulating the differentiation of
monocytes and immature DC into effective antigen presenting
cells [51]. An increased expression of chemokines and their
cognate receptors such as CXCL10 and CXCR3 direct cells to
the sites of inflammation, which is demonstrated by a reduced
number of pDCs in the peripheral blood of SLE patients [60].
With regard the adaptive immunity, type I IFNs prolong the
survival of activated T lymphocytes and stimulate the devel-
opment of CD4+ and CD8+ memory T cells. In addition, type
I IFN increase the differentiation of Th17 cells and suppress
Treg functions, which all can lead to an expansion of
autoreactive T cells and enhanced inflammatory responses
[54].
Concerning the effects on B cells, type I IFNs increase the
production of B-lymphocyte stimulator (BLyS), B cell prolif-
eration and lower the threshold required for activation through
the B cell receptor. The antibody production is effectuated via
increased immunoglobulin isotype class switch, differentia-
tion into plasma cell, and enhanced antibody production
[55–57].
The type I IFNs have also effects outside the immune sys-
tem, and an important one in the SLE context is the impair-
ment of endothelial function by induction of apoptosis and
slowing down the repair process of damaged endothelium
[58]. One can speculate that pDCs activated by interferogenic
ICs and inflammatory NETs formed in situ within the blood
vessel could be linked to the unexpectedly high prevalence of
atherosclerosis and cardiovascular disease in young female
SLE patients [59].
Clearly, a persistent synthesis of type IFNs has many cru-
cial effects on the immune system that can contribute to the
loss of tolerance and exacerbate the immune pathology in
individuals prone to autoimmune disorders.
Regulation of the IFN system in SLE
Normally, the IFN-α production is terminated after the path-
ogen has been eradicated and pDCs become temporally re-
fractory to new stimuli due to inhibition and degradation of
transcription factors and signal transducers [53, 61]. The sta-
bility of type I IFN mRNAs themselves can also be regulated
by micro-RNAs or factors binding to AU-rich elements [61].
However, the impact of cellular communication on the regu-
lation of the type I IFN production is largely overlooked. We
have therefore investigated several aspects of the cellular
cross-talk and showed that interactions between pDCs and
monocytes, NK cells, B cells, and activated T cells in a com-
plex network canmodulate the type I IFN production by pDCs
(see Fig. 1).We previously demonstrated that monocytes from
healthy individuals effectively reduced the IFN-α production
by pDCs stimulated with RNA-containing ICs consisting of
U1 snRNP and SLE-IgG (RNA-IC). The suppression was
mediated via reactive oxygen species, TNF-α, and prostaglan-
din E2 [62]. Interestingly, monocytes isolated from patients
with SLE did not have such strong suppressive capacity and
could represent a component contributing to the dysregulated
type I IFN system in the SLE.
In contrast to monocytes, it was shown that NK cells, B
cells, and activated T cells have the capacity to strongly en-
hance the RNA-IC-stimulated IFN-α production by pDCs
[62–64]. Themechanism for the stimulatory effect of NK cells
involves the production of adhesion molecule LFA-1 and
MIP-1β the latter triggered via FcRγIIIa (CD16) on NK cells
[65]. The stimulatory effect was entirely mediated by
CD56dim CD16+ NK cells, but the CD56bright CD16+ NK
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cells became equally effective after exposure to IL-12/IL-18.
In comparison, NK cells isolated from patients with SLE had a
reduced stimulatory effect on the IFN-α production by pDCs,
but in similar manner as the CD56bright CD16+ NK cells from
healthy individuals, the patient NK cells became stimulatory
when cultivated with IL-12 and IL-18 [65]. The stimulatory
capacity of the B cells on the IFN-α production by RNA-IC
activated pDCs was dependent on direct cell contact and was
abolished by blocking the endothelial cell adhesion molecule
(PECAM-1/CD31) [63]. The CD31 is a cell surface receptor
expressed on both B cells and pDCs [63, 66] and the cytosolic
part of the CD31 contains two tyrosine-based inhibitory mo-
tifs (ITIMs). Interestingly, it was recently reported that CD31
acts as a co-inhibitory receptor in activated conventional DCs
and prevented formation of functional immunological synap-
ses between T and B cells [67]. In contrast, when a TLR9
analog was used as stimulus there was no requirement for
direct cell contact or involvement of CD31 for the enhancing
effect of B cells. The difference of CD31 involvement could
have implications in situations when the goal is to block the
type I IFN production triggered by RNA containing IC via
TLR7 while leaving the TLR9 pathway intact. We recently
demonstrated that also activated T cells have the capacity to
enhance the IFN-α production by RNA-IC stimulated pDCs
[64]. After pre-activation, T cells from SLE patients and from
healthy individuals were equally effective in their stimu-
latory capacity [64]. The enhancing effect on the IFN-α
production by pDCs was largely mediated by the cytokine
GM-CSF and to a lesser extent by IL-3 [64]. This could
Table 1 Effects of interferon-alpha
Target cell Effects
NK cells Increased cytolytic activity [51]
Macrophages Enhanced intracellular killing of pathogens
and expression of co-stimulatory
molecules [51]
Dendritic cells Maturation, enhanced antigen presentation
[49]
Plasmacytoid DC Enhanced type I IFN production, homing to
lymph nodes [15, 16, 53]
CD4+ T cells Prolonged survival, promotion of Th1
profile, increased IL-12R expression,
generation of memory cells [49]
CD8+ cytotoxic T cells Enhanced cytotoxity, inhibition of apoptosis
[49]
Regulatory T cells Suppression of Treg activity [49, 54, 55]
Th17 T cells Skewing of Th cells towards Th17 profile
and IL-17 production [49, 54, 55]
B cells Increased plasma cell differentiation, isotype
switch, and enhanced antibody
production, generation of memory cells
[56, 57]














Fig. 1 Type I interferon production is affected by interactions between
plasmacytoid dendritic cells and other cell types. Plasmacytoid dendritic
cells (pDCs) produce type I interferon (IFN) when stimulated with RNA
containing immune complexes (RNA-IC). Activated monocytes/
macrophages suppress the capacity of pDCs to produce type I IFN by
releasing reactive oxygen species (ROS) and prostaglandin E2 (PGE2). In
contrast, NK cells enhance the type I IFN production by activated pDCs
via lymphocyte-associated antigen (LFA)-1 and secretion of MIP-1β.
Also, the B cells and activated T cells increase the type I IFN
production by RNA-IC-stimulated pDCs via a mechanisms involving
CD31 molecule and soluble GM-CSF, respectively
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reflect the in vivo situation in a subset of SLE patients
with the presence of hyperactivated T cells and increased
levels of GM-CSF [64].
In summary, the type I IFN production by pDCs and other
cell types can be enhanced or suppressed by several different
mechanisms. Obviously, several components in the cellular
pathways involved in type I IFN signaling, recognition of
nucleic acids, and clearance can either increase or decrease
the levels of type I IFN. How the pDCs escape the negative
feedback mechanisms in SLE and other disorders with persis-
tently activated type I IFN system remains to be further
clarified.
Therapeutic options
There are several possibilities to downregulate the type I IFN
system in SLE, and at the moment, a number of clinical trials
are in progress, reviewed in [5]. Among standard therapies for
SLE, both high doses of glucocorticosteroids and
hydroxychloroquine downregulate the IFN signature, but to-
day, more specific inhibitors of the type I IFN system exist.
Thus, three different monoclonal anti-IFN-α antibodies have
been developed, which at least partially decrease the IFN sig-
nature and disease activity [5]. A more complete inhibition of
the type I IFNs is to target the IFNAR, and recently, the first
results from treatment of SLE with an anti-IFNAR antibody
were reported [68]. In this study, there was an ∼90 % suppres-
sion of the IFN signature and a significant improvement in
disease activity, but at the cost of an increased frequency of
viral infections. New therapeutic strategies are to degrade the
stimulatory TLR ligands in interferogenic ICs by nucleases or
to use inhibitory oligodeoxynucleotides to block TLR activa-
tion [69]. A broader therapeutic approach is to target the pDCs
themselves withmonoclonal antibodies against BDCA-2 [70],
or to use proteasome inhibitors which efficiently suppress
production of IFN-α by TLR-activated PDCs [71]. When
the exact mechanisms behind the IFN signature in individual
patients can be identified, more specific drugs for the relevant
pathogenic pathway can be expected to be developed. One
possibility could be administration of reverse transcriptase
inhibitors for SLE patients with chronic stimulation of DNA
sensors by retroelement cDNA [72]. A more personalized
approach to modulate the type I IFN system in order to reduce
the risk for increased frequency and severity of infectious
diseases would be a major therapeutic leap forward for this
vulnerable group of patients.
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